Objective: This study aims to compare the effect of thromboembolic prophylaxis in patients diagnosed with hypertensive disorders of pregnancy undergoing cesarean section.
Methods: Three hundred and eighty-six patients were included in the study. The patients were divided into groups according to the type of hypertensive disorders of pregnancy and whether thromboembolism prophylaxis was applied or not. The thromboembolic event incidence and other pregnancy outcomes were compared.
Results: Nonadministration of thromboprophylaxis was recorded in 210 patients. Eleven patients had thromboembolic events (5%). Among 176 patients who received thromboprophylaxis, only two patients (1%) had a thromboembolic event (p<0.05).
Conclusion: There is an increased tendency to thromboembolism in pregnancy. The incidence increases in the presence of hypertension accompanying pregnancy. In our study, the importance of thromboembolism prophylaxis on peri-postnatal complications in patients with hypertensive disorders of pregnancy was emphasized.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170378 | PMC |
| http://dx.doi.org/10.14744/nci.2021.68726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension.
JAMA Netw Open
January 2025
Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, Epidemiology and Clinical and Translational Research, University of Pittsburgh, Pittsburgh, Pennsylvania.
Importance: Chronic hypertension and preeclampsia are leading risk enhancers for maternal-neonatal morbidity and mortality. Severe maternal morbidity (SMM) indicators include heart, kidney, and liver disease, but studies have not excluded patients with preexisting diseases that define SMM. Thus, SMM risks for uncomplicated chronic hypertension specific to preeclampsia remain unclear.
View Article and Find Full Text PDFLong-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.
Int J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFPelvic ring fracture and erectile dysfunction (PERFECD) - 3 year follow-up cross sectional study.
Eur J Trauma Emerg Surg
January 2025
Faculty of Medicine, University of Zurich, Raemistrasse 71, 8006, Zurich, Switzerland.
Introduction: Pelvic ring fractures are known to be associated with complications associated with adjacent organ injuries, such as the urogenital tract (e.g. erectile dysfunction (ED), which are sometimes diagnosed in a delayed fashion.
View Article and Find Full Text PDFEffectiveness and safety of the use of sodium nitrite in patients with hypertension and pulmonary hypertension: a scoping review.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Biological Sciences, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto, Brazil.
Evidence suggests that sodium nitrite may be effective in the treatment of hypertension and pulmonary hypertension. However, its use remains debated due to safety concerns. In response, a scoping review was conducted to map current knowledge on the efficacy and safety of sodium nitrite in patients with hypertension or pulmonary hypertension, addressing the question: What evidence supports the effectiveness and safety of using sodium nitrite in these patients? The databases MEDLINE (PubMed), EMBASE, Scopus, Web of Science, and LILACS were searched for clinical studies on hypertensive patients at any disease stage without restrictions on age, sex, ethnicity, publication date, or status.
View Article and Find Full Text PDFPulmonary vascular complications of cirrhosis: hepatopulmonary syndrome and portopulmonary hypertension.
Acta Clin Belg
January 2025
Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are two distinct pulmonary vascular complications seen in patients with liver disease and/or portal hypertension. HPS is characterized by disturbed gas exchange and hypoxemia because of intrapulmonary vascular dilatations. POPH is defined by pulmonary arterial hypertension, which might lead to right heart failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!